Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vir Biotechnology Inc (NQ: VIR ) 8.650 -0.120 (-1.37%) Streaming Delayed Price Updated: 12:45 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 156,165 Open 8.820 Bid (Size) 8.640 (6) Ask (Size) 8.660 (4) Prev. Close 8.770 Today's Range 8.540 - 8.845 52wk Range 7.610 - 13.27 Shares Outstanding 133,976,538 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 22, 2024 From Vir Biotechnology, Inc. Via Business Wire Breaking Down Vir Biotechnology: 6 Analysts Share Their Views August 02, 2024 Via Benzinga Performance YTD -17.70% -17.70% 1 Month -19.16% -19.16% 3 Month -19.38% -19.38% 6 Month -27.31% -27.31% 1 Year -34.02% -34.02% More News Read More VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024 August 01, 2024 Via InvestorPlace Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities August 01, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers August 01, 2024 From Vir Biotechnology, Inc. Via Business Wire Evaluating Vir Biotechnology: Insights From 5 Financial Analysts May 24, 2024 Via Benzinga Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark July 26, 2024 Via Investor's Business Daily Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 July 18, 2024 From Vir Biotechnology, Inc. Via Business Wire 3 Undervalued Biotech Gems With 200%+ Analyst Price Targets July 04, 2024 Via InvestorPlace Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection June 26, 2024 From Vir Biotechnology, Inc. Via Business Wire Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings) May 07, 2024 Via Benzinga Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? June 05, 2024 Via Benzinga Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session June 05, 2024 Via Benzinga Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday June 05, 2024 Via Benzinga Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment June 05, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 29, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer May 29, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology to Host 2024 Annual Meeting of Stockholders May 23, 2024 From Vir Biotechnology, Inc. Via Business Wire Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 May 22, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 May 21, 2024 From Vir Biotechnology, Inc. Via Business Wire VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 May 02, 2024 Via InvestorPlace Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results May 02, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 April 30, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors April 18, 2024 From Vir Biotechnology, Inc. Via Business Wire Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 April 11, 2024 From Vir Biotechnology, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
